Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.


Date Title Topic
19 Jun 2017 Catalyzing Integration of Genomic and Clinical Datasets Across Multiple Cancer Institutions Worldwide Translational research
16 Jun 2017 NICE Issues Technology Appraisal Guidance for Brentuximab Vedotin in CD30-Positive Hodgkin Lymphoma Haematologic malignancies - Anticancer agents & Biologic therapy
14 Jun 2017 EMA – PRAC Concludes There Is No Evidence of a Change in Known Risk of Neutropenic Enterocolitis With Docetaxel Anticancer agents & Biologic therapy
13 Jun 2017 FDA Approves Aminolevulinic Acid Hydrochloride as an Optical Imaging Agent Indicated in Patients with Gliomas Diagnosis, Imaging and Staging - Central nervous system malignancies
12 Jun 2017 T-DM1 in HER2 Overexpressing, Amplified or Mutated Metastatic NSCLC Translational research - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
09 Jun 2017 Routine Molecular Screening of Advanced Refractory Cancer Patients Personalised medicine
08 Jun 2017 EMA Adopts a Negative Opinion for Human IgG1 mAb Specific for Human Interleukin-1 Alpha XBiotech Gastrointestinal cancers
07 Jun 2017 Three Biosimilar Medicines with Rituximab as Active Substance Received a Positive Opinion from EMA Haematologic malignancies
06 Jun 2017 NICE Issues Quality Standard for Haematological Cancers Haematologic malignancies
02 Jun 2017 A Need to Harmonise the Prescribing Information for Etoposide in the EU Anticancer agents & Biologic therapy
01 Jun 2017 FDA Accepts for Priority Review Application for Nivolumab in Previously Treated Hepatocellular Carcinoma Gastrointestinal cancers - Cancer Immunology and Immunotherapy
31 May 2017 FDA Broadens Ceritinib Indication to Previously Untreated ALK-positive Metastatic NSCLC Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
30 May 2017 NICE Terminates Technology Appraisal for Afatinib in Advanced Squamous NSCLC After Platinum-based Chemotherapy Lung and other thoracic tumours - Anticancer agents & Biologic therapy
29 May 2017 FDA Grants Accelerated Approval to Pembrolizumab for Unresectable or Metastatic MSI-H or dMMR Solid Tumours Cancer Immunology and Immunotherapy
26 May 2017 Withdrawal of the Marketing Authorisation Application for Vosaroxin Haematologic malignancies - Anticancer agents & Biologic therapy